PTC Therapeutics (PTCT) Q1 2025 earnings summary

Executive summary

• Achieved Q1 2025 revenue of $1.18 billion, driven by a $986.2 million Novartis upfront payment and strong DMD franchise and royalty income.

• Net income reached $866.6 million for Q1 2025, compared to a net loss of $91.6 million in Q1 2024.

• Advanced global launch preparations for Sephience, with positive CHMP opinion and anticipated broad PKU label; NDA review on track for July 29, 2025 PDUFA date.

• Maintained robust regulatory progress for Sephience, vatiquinone, and Translarna NDAs, with no delays from recent FDA changes.

• Ended Q1 with over $2 billion in cash, supporting all commercial and R&D activities and providing insulation from macro uncertainties.

Financial highlights

• Q1 2025 total revenue was $1.18 billion, up from $210.1 million in Q1 2024, driven by the Novartis agreement.

• Net product revenue was $153.4 million, down 14% year-over-year; DMD franchise contributed $134 million, Translarna $86.2 million, Emflaza $47.8 million.

• Royalty revenue from Roche's SMA/Evrysdi product was $36.4 million, up 17% year-over-year.

• Collaboration and license revenue surged to $986.2 million, reflecting the Novartis agreement.

• Cash, cash equivalents, and marketable securities totaled $2.03 billion as of March 31, 2025.

Outlook and guidance

• 2025 full-year revenue guidance narrowed to $650–$800 million, with further refinement expected pending regulatory actions and influenza performance.

• Confident in achieving cash flow break-even, timing dependent on PKU sales ramp and FDA outcomes for vatiquinone and Translarna.

• Expects significant revenue contributions from Sephience in Europe and the U.S. in the second half of 2025.

• Anticipates full-year 2025 GAAP R&D and SG&A expenses of $805–$835 million; non-GAAP R&D and SG&A expenses expected at $730–$760 million.

• Cash flows from product sales, royalties, milestone payments, and existing cash expected to fund operations for at least the next 12 months.